Does Blue Cross Blue Shield of Arizona Cover Novolog?

What Is Novolog and Why Does Formulary Placement Matter?

Novolog is the brand name for insulin aspart, a rapid-acting insulin analog manufactured by Novo Nordisk. The FDA first approved insulin aspart in June 2000 under NDA 020986, and it remains one of the most widely prescribed mealtime insulins in the United States. 1 Formulary placement determines how much you pay at the pharmacy counter, and the difference between a preferred Tier 2 and a non-preferred Tier 3 listing can mean $50 to $150 more per month out of pocket.

How Insulin Formulary Tiers Work

Most commercial insurance plans organize drugs into three to five tiers. Tier 1 contains generic or preferred generic drugs with the lowest copay. Tier 2 holds preferred brand-name drugs. Tier 3 covers non-preferred brands. Novolog historically sat at Tier 2 on most BCBS AZ plans, but since 2022 several BCBS AZ plan designs have shifted it to Tier 3 while placing biosimilar insulin aspart products or Novolin (regular human insulin) at Tier 1 or Tier 2. 2

The American Diabetes Association's 2024 Standards of Care state: "Insulin access and affordability remain major barriers to optimal diabetes management, and clinicians should proactively identify insurance coverage, patient assistance programs, and alternative formulations for every insulin-dependent patient." 3

Rapid-Acting Insulin Options BCBS AZ May Prefer Over Novolog

When a plan moves Novolog to a higher tier, it typically prefers one of the following at a lower cost-share tier:

• Admelog (insulin lispro-aabc), a biosimilar to Humalog approved by the FDA in December 2017 4
• Lyumjev (insulin lispro-aabc), a faster-acting lispro formulation approved in June 2020 5
• Novolin R, regular human insulin available over the counter at Walmart for $25 per vial, though its pharmacokinetic profile differs meaningfully from rapid-acting analogs 6

Your prescribing physician can document a medical necessity exception if these alternatives are clinically inappropriate for you.

Prior Authorization Requirements for Novolog on BCBS AZ Plans

Prior authorization (PA) is a pre-approval process your insurer requires before it will cover a specific drug. BCBS AZ imposes PA on Novolog on several of its commercial plan designs, particularly the BlueSelect and BluePPO tiers where Novolog sits at Tier 3. PA criteria typically include documentation that the member has a diagnosis of Type 1 or Type 2 diabetes requiring rapid-acting insulin and, on some plans, evidence that a preferred formulary insulin was trialed for at least 30 days and did not achieve glycemic targets. 7

What Your Doctor Must Submit

A complete PA request for Novolog on BCBS AZ generally requires:

• A copy of the most recent HbA1c result (dated within 90 days)
• Documentation of the diabetes type and duration of insulin therapy
• Clinical notes showing why the preferred alternative is unsuitable (e.g., allergy, hypoglycemia pattern, documented treatment failure)
• The prescribing physician's DEA number and NPI

The ADA advises clinicians: "When prior authorization is required for insulin, the clinical team should submit requests with complete documentation to avoid unnecessary delays in therapy." 3 BCBS AZ is required under Arizona Administrative Code R20-6-801 to issue a PA decision within 72 hours for non-urgent requests and within 24 hours for urgent requests. 8

Step Therapy: Does BCBS AZ Require It?

Step therapy means the plan requires you to try and fail a preferred drug before approving the non-preferred one. Several BCBS AZ employer-sponsored plans include a step-therapy requirement for Novolog, asking that members first try Novolin R or a biosimilar insulin aspart product. Arizona HB 2303 (enacted 2019) limits step therapy for certain chronic-condition drugs and requires insurers to grant step-therapy exceptions when a prescriber documents clinical reasons. If you are already stable on Novolog, your physician can invoke this exception and bypass the trial period. 9

How to Check Your Specific BCBS AZ Plan's Novolog Coverage

Formulary coverage is plan-specific. The same BCBS AZ logo on your card can cover dozens of distinct plan designs, each with a different drug formulary. Follow these steps:

1. Locate your plan name and group number on your insurance card.
2. Visit the BCBS AZ member portal at azblue.com and select "Find a Drug."
3. Search "insulin aspart" or "NovoLog" and filter by your plan year.
4. Note the tier, any quantity limits (typically 10 mL vials or 5-pen boxes per 30-day fill), and whether PA is flagged.
5. Call the pharmacy benefits number (on the back of your card) to confirm PA status before your pharmacy submits the claim.

The FDA's guidance on biosimilar interchangeability 2 notes that a pharmacist may substitute an interchangeable biosimilar without contacting the prescriber, so verify with both your pharmacy and your insurer which product will actually be dispensed.

Reading the BCBS AZ Formulary PDF

BCBS AZ publishes a full formulary PDF each plan year. Novolog appears under the drug class "Antidiabetic Agents, Insulin Analogs, Rapid-Acting." The formulary lists:

• Tier (1 through 5 on some plans)
• PA flag (if prior authorization is required)
• QL flag (quantity limit per 30 days)
• ST flag (step therapy required)

A plan without any flags next to Novolog covers it without restriction at the listed copay. A plan showing "PA/ST" means you need both a PA approval and documented step therapy failure. Reviewing this PDF before your plan year begins saves time at the pharmacy.

Out-of-Pocket Costs for Novolog Under BCBS AZ

Cost-sharing for Novolog varies by plan design. Below are the approximate ranges you can expect on BCBS AZ commercial plans in 2025:

| Plan Type | Tier Placement | Estimated Monthly Copay | |---|---|---| | BlueSelect Silver | Tier 3 | $60 to $90 per box of 5 pens | | BluePPO Gold | Tier 2 | $35 to $55 per box of 5 pens | | HDHP (HSA-eligible) | Tier 3 | Full cost until deductible met | | Medicare Advantage (AZ) | Tier 3 | $47 copay in coverage phase |

The $35 ACA Insulin Cap

The Inflation Reduction Act of 2022 capped insulin cost-sharing at $35 per 30-day supply on all Medicare Part D plans starting January 1, 2023. 10 For ACA Marketplace plans (not employer-sponsored plans), the $35 cap on insulin took effect January 1, 2023, under HHS regulations. If your BCBS AZ plan is purchased through the ACA Marketplace (Healthcare.gov), your Novolog cost-sharing cannot exceed $35 per 30-day fill regardless of formulary tier. Employer-sponsored plans are not bound by this cap unless the employer opts into it voluntarily.

High-Deductible Plans and Insulin

A 2021 Health Affairs study (N=236,000 commercially insured diabetes patients) found that patients in high-deductible health plans (HDHPs) were 27% more likely to report cost-related insulin rationing compared with patients in traditional copay plans. 11 If your BCBS AZ plan is an HDHP, you will pay the full negotiated rate for Novolog until your deductible is met. The negotiated rate for a box of five Novolog FlexPens (15 mL total) typically ranges from $180 to $340 depending on pharmacy and plan contract. An HSA can cover insulin purchases tax-free, which reduces effective out-of-pocket cost.

Savings Programs That Work Alongside BCBS AZ Coverage

Several programs reduce Novolog costs even when insurance coverage is incomplete.

Novo Nordisk Savings Card

Novo Nordisk offers an insulin savings card (sometimes called the Novolog Savings Offer) that caps out-of-pocket cost at $99 per 30-day supply for eligible commercially insured patients. The savings card is not valid for Medicare, Medicaid, or any government-funded plan. You can enroll at novocare.com. Because BCBS AZ commercial plans are private insurance, most BCBS AZ members qualify for this program.

Novo Nordisk Patient Assistance Program

The Novo Nordisk Patient Assistance Program (NovoCare PAP) provides free insulin, including Novolog, to uninsured and underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). 12 Applications are submitted at novocare.com or by calling 1-866-310-7549. A diagnosis of diabetes and a prescription from a licensed U.S. Prescriber are required.

GoodRx and Cash-Pay Options

GoodRx and similar discount platforms can bring the cash price of a Novolog FlexPen 5-pack to approximately $160 to $220 at Arizona pharmacies. Using GoodRx is mutually exclusive with submitting a claim to BCBS AZ for the same fill. If your BCBS AZ cost-share after deductible exceeds the GoodRx price, paying cash with a discount card may cost less. However, cash-pay purchases typically do not count toward your plan deductible or out-of-pocket maximum.

What to Do if BCBS AZ Denies Novolog Coverage

A denial is not the end of the road. BCBS AZ must provide a written denial notice that includes the specific reason and instructions for appeal.

Internal Appeal

You have 180 days from the denial date to file an internal appeal with BCBS AZ. Submit a written appeal including:

• The original denial letter
• A letter from your physician explaining medical necessity
• Any clinical literature supporting Novolog over the preferred alternative (for example, data showing that insulin lispro and insulin aspart have clinically distinct absorption profiles in certain patients) 13
• Your most recent lab results (HbA1c, fasting glucose log)

BCBS AZ must respond to an internal appeal within 30 days for non-urgent cases and 72 hours for urgent/expedited cases under Arizona law and the ACA. 8

External Review

If BCBS AZ upholds the denial, Arizona law entitles you to an independent external review by an independent review organization (IRO) approved by the Arizona Department of Insurance. The IRO decision is binding on the insurer. The external review request must be filed within 4 months of the final internal denial notice. Studies show that external review reversal rates for medication denials range from 39% to 59% depending on drug class. 14

State and Federal Escalation

If BCBS AZ fails to process appeals within legally required timeframes, file a complaint with the Arizona Department of Insurance and Financial Institutions (DIFI) at azinsurance.gov. Federal complaints can be filed with CMS at cms.gov if the plan is ACA-compliant.

Clinical Context: Why Novolog Specifically Matters for Glycemic Control

Switching insulins is not purely a formulary-administrative exercise. Rapid-acting insulin analogs differ in their time-action profiles, and substituting one for another can alter postprandial glucose control.

Pharmacokinetics of Insulin Aspart vs. Regular Human Insulin

Novolog (insulin aspart) reaches peak serum concentration approximately 40 to 50 minutes after subcutaneous injection, with a duration of action of 3 to 5 hours. Regular human insulin (Novolin R) peaks at 2 to 4 hours and acts for 5 to 8 hours. A 2000 pharmacokinetic study (N=18 Type 1 diabetes patients) published in Diabetes Care found that insulin aspart produced significantly lower postprandial glucose excursions (mean 2.1 mmol/L lower at 90 minutes, P<0.001) compared with regular insulin when injected 15 minutes before a meal. 15 Patients using Novolin R as a formulary substitute must adjust injection timing (30 minutes before meals), which introduces adherence complexity.

Evidence in Type 1 Diabetes

The DCCT (Diabetes Control and Complications Trial, N=1,441) established that intensive glycemic control reduces microvascular complications by 35% to 76% depending on the outcome measure. 16 While DCCT predated insulin analogs, subsequent trials confirmed that rapid-acting analogs reduce HbA1c and lower rates of nocturnal hypoglycemia compared with regular insulin. A Cochrane review (2016, 8 RCTs, N=2,101 Type 1 patients) found insulin aspart reduced HbA1c by 0.1% more than regular insulin (P<0.05) and cut severe hypoglycemia events by 18% (relative risk 0.82, 95% CI 0.70 to 0.97). 17

Evidence in Type 2 Diabetes

The UKPDS 33 trial (N=3,867 Type 2 patients) showed that intensive blood glucose control reduces microvascular endpoints by 25% (P<0.0099). 18 For Type 2 patients requiring prandial insulin, rapid-acting analogs like insulin aspart offer post-meal control flexibility that human insulin cannot match for patients with unpredictable meal timing.

Comparing Novolog to Formulary-Preferred Alternatives on BCBS AZ

Understanding the clinical differences helps you and your doctor make the case for Novolog when a formulary alternative is not appropriate.

Insulin Aspart Biosimilar (Admelog)

Admelog (insulin lispro-aabc) is technically a biosimilar of Humalog (insulin lispro), not a biosimilar of Novolog. It has a slightly different molecular structure from insulin aspart. While both are rapid-acting analogs with similar pharmacokinetic profiles, they are not therapeutically identical at the molecular level. The FDA has approved Admelog as interchangeable with Humalog but has not designated Admelog as interchangeable with Novolog. 4 This distinction matters for formulary exception requests.

Fiasp (Faster Insulin Aspart)

Fiasp is a faster-acting formulation of insulin aspart approved by the FDA in September 2017. 19 It contains niacinamide as an absorption enhancer, producing an onset of action approximately 5 minutes faster than Novolog. BCBS AZ formulary placement of Fiasp varies; on some plans it sits at a lower tier than standard Novolog for patients using insulin pumps (continuous subcutaneous insulin infusion). If your BCBS AZ plan covers Fiasp at a lower tier and you use a pump, switching may be clinically reasonable and financially beneficial.

Annual Formulary Changes and How to Stay Ahead

BCBS AZ updates its formularies on January 1 each year. Drugs can move between tiers, gain PA requirements, or be removed entirely with 60 days' advance written notice to affected members. The 2024 to 2025 transition saw several BCBS AZ plans remove brand Novolog from Tier 2 and add PA requirements that did not exist in the prior year.

Set a calendar reminder each October to review your plan's updated formulary for the upcoming plan year. The Summary of Benefits and Coverage (SBC) document, available at AZBlue.com, outlines drug coverage changes. If Novolog moves to a less favorable tier, your physician can submit a PA request proactively before January 1 so coverage is in place on day one of the new plan year.

The ADA 2024 Standards of Care explicitly recommend: "Clinicians should review patients' insulin coverage at each annual visit, particularly at plan year transitions, and submit prior authorization renewals at least 30 days before expiration." 3